node1	node2	edge_score	
DB00072	ERBB2	1.0	
DB00072	FCGR2B	1.0	
DB00072	EGFR	1.0	
DB00072	CYP19A1	1.0	
DB00072	C1QC	1.0	
DB00072	FCGR2C	1.0	
DB00072	C1QA	1.0	
DB00072	FCGR2A	1.0	
DB00072	FCGR1A	1.0	
DB00072	C1S	1.0	
DB00072	C1R	1.0	
DB00072	FCGR3A	1.0	
DB00072	FCGR3B	1.0	
DB00072	C1QB	1.0	
ERBB2		1.0
CYP19A1	rs10046	0.99
CYP19A1	rs3759811	0.99
CYP19A1	rs700518	0.99
CYP19A1	rs2289105	0.99
UBC	TRAF6	0.863464374084
CYP19A1	rs4646	0.99
CYP19A1	rs7176005	0.99
FCGR2B		1.0
EGFR	rs712830	0.99
CYP19A1		1.0
EGFR	rs121434568	0.99
EGFR	rs712829	0.99
CYP19A1	rs1008805	0.99
EGFR	rs121434569	0.99
CYP19A1	rs4775936	0.99
CYP19A1	rs2236722	0.99
EGFR	UBC	0.935012238275
EGFR	rs11568315	0.99
EGFR	rs2227983	0.99
EGFR	rs2293347	0.99
CYP19A1	rs1062033	0.99
EGFR		1.0
CYP19A1	rs749292	0.99
FCGR3A		1.0
FCGR2A		1.0
CYP19A1	rs6493497	0.99
Lichen Planus, Oral	EGFR	1.0	
Lichen Planus, Oral	ERBB2	1.0	
Lichen Planus, Oral	FCGR2A	1.0	
Lichen Planus, Oral	FCGR2B	1.0	
Lupus Vulgaris	EGFR	1.0	
Lupus Vulgaris	ERBB2	1.0	
Lupus Vulgaris	FCGR2A	1.0	
Lupus Vulgaris	FCGR2B	1.0	
Lupus Vulgaris	FCGR3A	1.0	
Lupus Vulgaris	TRAF6	1.0	
Discoid lupus erythematosus	EGFR	1.0	
Discoid lupus erythematosus	ERBB2	1.0	
Discoid lupus erythematosus	FCGR2A	1.0	
Discoid lupus erythematosus	FCGR2B	1.0	
Discoid lupus erythematosus	FCGR3A	1.0	
Discoid lupus erythematosus	TRAF6	1.0	
Malignant neoplasm of male breast	CYP19A1	1.0	
Malignant neoplasm of male breast	EGFR	1.0	
Malignant neoplasm of male breast	ERBB2	1.0	
{Systemic lupus erythematosus, susceptibility to, 8} (2)	EGFR	1.0	
{Systemic lupus erythematosus, susceptibility to, 8} (2)	ERBB2	1.0	
{Systemic lupus erythematosus, susceptibility to, 8} (2)	FCGR2A	1.0	
{Systemic lupus erythematosus, susceptibility to, 8} (2)	FCGR2B	1.0	
{Systemic lupus erythematosus, susceptibility to, 8} (2)	FCGR3A	1.0	
{Systemic lupus erythematosus, susceptibility to, 8} (2)	TRAF6	1.0	
Anti-Glomerular Basement Membrane Disease	FCGR2A	1.0	
Anti-Glomerular Basement Membrane Disease	FCGR2B	1.0	
Anti-Glomerular Basement Membrane Disease	FCGR3A	1.0	
Giant cell arteritis	FCGR2A	1.0	
Giant cell arteritis	FCGR2B	1.0	
Giant cell arteritis	FCGR3A	1.0	
Giant cell arteritis	TRAF6	1.0	
Carcinoma of Male Breast	CYP19A1	1.0	
Carcinoma of Male Breast	EGFR	1.0	
Carcinoma of Male Breast	ERBB2	1.0	
Meningococcal Infections	FCGR2A	1.0	
Meningococcal Infections	FCGR2B	1.0	
Meningococcal Infections	FCGR3A	1.0	
Breast Fibrocystic Disease	CYP19A1	1.0	
Breast Fibrocystic Disease	EGFR	1.0	
Breast Fibrocystic Disease	ERBB2	1.0	
Malignant neoplasm of brain and nervous system	EGFR	1.0	
Malignant neoplasm of brain and nervous system	ERBB2	1.0	
Malignant neoplasm of brain and nervous system	FCGR2A	1.0	
Malignant neoplasm of brain and nervous system	FCGR3A	1.0	
Tumor necrosis	EGFR	1.0	
Tumor necrosis	ERBB2	1.0	
Tumor necrosis	FCGR3A	1.0	
Tumor necrosis	TRAF6	1.0	
{Pemphigoid, susceptibility to} (2)	FCGR2A	1.0	
{Pemphigoid, susceptibility to} (2)	FCGR2B	1.0	
{Pemphigoid, susceptibility to} (2)	FCGR3A	1.0	
Endometrioma	CYP19A1	1.0	
Endometrioma	EGFR	1.0	
Endometrioma	ERBB2	1.0	
Alveolar cell carcinoma	CYP19A1	1.0	
Alveolar cell carcinoma	EGFR	1.0	
Alveolar cell carcinoma	ERBB2	1.0	
Cholera	CYP19A1	1.0	
Cholera	EGFR	1.0	
Cholera	ERBB2	1.0	
Papillary adenocarcinoma	EGFR	1.0	
Papillary adenocarcinoma	ERBB2	1.0	
Estrogen resistance	EGFR	1.0	
Estrogen resistance	ERBB2	1.0	
Merkel cell carcinoma	EGFR	1.0	
Merkel cell carcinoma	ERBB2	1.0	
Merkel cell carcinoma	FCGR3A	1.0	
Periodontal Attachment Loss	FCGR2A	1.0	
Periodontal Attachment Loss	FCGR3A	1.0	
Breast cancer recurrent	EGFR	1.0	
Breast cancer recurrent	ERBB2	1.0	
Lupus Nephritis	ERBB2	1.0	
Lupus Nephritis	FCGR2A	1.0	
Lupus Nephritis	FCGR2B	1.0	
Lupus Nephritis	FCGR3A	1.0	
Thymic Carcinoma	EGFR	1.0	
Thymic Carcinoma	ERBB2	1.0	
Neoplasm of the thymus	EGFR	1.0	
Neoplasm of the thymus	FCGR2A	1.0	
Gastrinoma	EGFR	1.0	
Gastrinoma	ERBB2	1.0	
Hypohidrotic X-linked ectodermal dysplasia	EGFR	1.0	
Hypohidrotic X-linked ectodermal dysplasia	TRAF6	1.0	
Periodontal Pocket	FCGR2A	1.0	
Periodontal Pocket	FCGR3A	1.0	
Stage IV Ovarian Carcinoma	EGFR	1.0	
Stage IV Ovarian Carcinoma	ERBB2	1.0	
Complete hydatidiform mole	EGFR	1.0	
Complete hydatidiform mole	ERBB2	1.0	
Primary Lesion	EGFR	1.0	
Primary Lesion	ERBB2	1.0	
Idiopathic thrombocytopenic purpura	FCGR2A	1.0	
Idiopathic thrombocytopenic purpura	FCGR2B	1.0	
Idiopathic thrombocytopenic purpura	FCGR3A	1.0	
Pericardial effusion	EGFR	1.0	
Pericardial effusion	ERBB2	1.0	
Comedone	EGFR	1.0	
Comedone	ERBB2	1.0	
Prostate cancer recurrent	EGFR	1.0	
Prostate cancer recurrent	ERBB2	1.0	
Sentinel node (disorder)	EGFR	1.0	
Sentinel node (disorder)	ERBB2	1.0	
Nodule	CYP19A1	1.0	
Nodule	EGFR	1.0	
Nodule	ERBB2	1.0	
Ovarian cyst	CYP19A1	1.0	
Ovarian cyst	EGFR	1.0	
Ovarian cyst	ERBB2	1.0	
Meningitis	ERBB2	1.0	
Meningitis	FCGR2A	1.0	
Meningitis	FCGR3A	1.0	
Recurrent bacterial infection	EGFR	1.0	
Recurrent bacterial infection	FCGR2A	1.0	
Recurrent bacterial infection	FCGR2B	1.0	
Recurrent bacterial infection	TRAF6	1.0	
Metastatic Carcinoma	EGFR	1.0	
Metastatic Carcinoma	ERBB2	1.0	
Alveolar Bone Loss	FCGR2A	1.0	
Alveolar Bone Loss	FCGR3A	1.0	
Malignant neoplasm of stomach stage IV	EGFR	1.0	
Malignant neoplasm of stomach stage IV	ERBB2	1.0	
Carcinoma, Endometrioid	CYP19A1	1.0	
Carcinoma, Endometrioid	EGFR	1.0	
Carcinoma, Endometrioid	ERBB2	1.0	
Alveolar proteinosis	FCGR2A	1.0	
Alveolar proteinosis	FCGR2B	1.0	
Neurofibromatoses	EGFR	1.0	
Neurofibromatoses	ERBB2	1.0	
Stromal sarcoma	CYP19A1	1.0	
Stromal sarcoma	EGFR	1.0	
Common variable immunodeficiency 2	FCGR2A	1.0	
Common variable immunodeficiency 2	FCGR2B	1.0	
Common variable immunodeficiency 2	FCGR3A	1.0	
CNS metastases	EGFR	1.0	
CNS metastases	ERBB2	1.0	
Idiopathic crescentic glomerulonephritis	EGFR	1.0	
Idiopathic crescentic glomerulonephritis	FCGR3A	1.0	
Diffuse Scleroderma	FCGR2A	1.0	
Diffuse Scleroderma	FCGR3A	1.0	
Carcinosarcoma	EGFR	1.0	
Carcinosarcoma	ERBB2	1.0	
Erythroblastosis	EGFR	1.0	
Erythroblastosis	ERBB2	1.0	
Primary malignant neoplasm of brain	EGFR	1.0	
Primary malignant neoplasm of brain	ERBB2	1.0	
Gestational trophoblastic disease	EGFR	1.0	
Gestational trophoblastic disease	ERBB2	1.0	
Single tumor	EGFR	1.0	
Single tumor	ERBB2	1.0	
Primary Carcinoma	EGFR	1.0	
Primary Carcinoma	ERBB2	1.0	
Oropharyngeal disorders	EGFR	1.0	
Oropharyngeal disorders	ERBB2	1.0	
Mammary Carcinoma, Human	EGFR	1.0	
Mammary Carcinoma, Human	ERBB2	1.0	
Neoplasm of the respiratory system	EGFR	1.0	
Neoplasm of the respiratory system	ERBB2	1.0	
Sickle Cell Trait	FCGR2A	1.0	
Sickle Cell Trait	FCGR2B	1.0	
Li-Fraumeni syndrome	EGFR	1.0	
Li-Fraumeni syndrome	ERBB2	1.0	
Neck Neoplasms	EGFR	1.0	
Neck Neoplasms	ERBB2	1.0	
Neoplasm of the gallbladder	EGFR	1.0	
Neoplasm of the gallbladder	ERBB2	1.0	
Papillomavirus Infections	EGFR	1.0	
Papillomavirus Infections	ERBB2	1.0	
Pneumococcal Infections	FCGR2A	1.0	
Pneumococcal Infections	FCGR2B	1.0	
stage, non-small cell lung cancer	EGFR	1.0	
stage, non-small cell lung cancer	ERBB2	1.0	
Graft-versus-host disease, susceptibility to	EGFR	1.0	
Graft-versus-host disease, susceptibility to	FCGR2A	1.0	
Graft-versus-host disease, susceptibility to	FCGR3A	1.0	
Graft-versus-host disease, susceptibility to	TRAF6	1.0	
Phyllodes tumor, benign	EGFR	1.0	
Phyllodes tumor, benign	ERBB2	1.0	
Uterine Cancer	EGFR	1.0	
Uterine Cancer	ERBB2	1.0	
Malignant neoplasm of female breast	CYP19A1	1.0	
Malignant neoplasm of female breast	ERBB2	1.0	
Guillain-Barre syndrome, familial	FCGR2A	1.0	
Guillain-Barre syndrome, familial	FCGR3A	1.0	
Non-Hodgkin lymphoma	CYP19A1	1.0	
Non-Hodgkin lymphoma	ERBB2	1.0	
Non-Hodgkin lymphoma	FCGR2A	1.0	
Non-Hodgkin lymphoma	FCGR3A	1.0	
Non-Hodgkin lymphoma	TRAF6	1.0	
Progressive Neoplastic Disease	EGFR	1.0	
Progressive Neoplastic Disease	ERBB2	1.0	
Progressive Neoplastic Disease	FCGR3A	1.0	
Progressive cGVHD	EGFR	1.0	
Progressive cGVHD	ERBB2	1.0	
Progressive cGVHD	FCGR3A	1.0	
Female Breast Carcinoma	CYP19A1	1.0	
Female Breast Carcinoma	ERBB2	1.0	
Nerve Sheath Tumors	EGFR	1.0	
Nerve Sheath Tumors	ERBB2	1.0	
Low Grade Squamous Intraepithelial Neoplasia	EGFR	1.0	
Low Grade Squamous Intraepithelial Neoplasia	ERBB2	1.0	
Carcinoma, Neuroendocrine	EGFR	1.0	
Carcinoma, Neuroendocrine	ERBB2	1.0	
Pneumonitis	FCGR2A	1.0	
Pneumonitis	FCGR3A	1.0	
Carcinoma breast stage IV	CYP19A1	1.0	
Carcinoma breast stage IV	EGFR	1.0	
Carcinoma breast stage IV	ERBB2	1.0	
Carcinoma breast stage IV	FCGR3A	1.0	
Infection by Cryptococcus neoformans	FCGR2A	1.0	
Infection by Cryptococcus neoformans	FCGR3A	1.0	
Female pseudohermaphroditism	CYP19A1	1.0	
Female pseudohermaphroditism	EGFR	1.0	
Human papilloma virus infection	EGFR	1.0	
Human papilloma virus infection	ERBB2	1.0	
EPIDERMODYSPLASIA VERRUCIFORMIS	ERBB2	1.0	
EPIDERMODYSPLASIA VERRUCIFORMIS	FCGR3A	1.0	
Oropharyngeal squamous cell carcinoma	EGFR	1.0	
Oropharyngeal squamous cell carcinoma	ERBB2	1.0	
Cachexia	EGFR	1.0	
Cachexia	TRAF6	1.0	
Cachexia	UBC	1.0	
cancer recurrence	EGFR	1.0	
cancer recurrence	ERBB2	1.0	
Adenocarcinoma, Endometrioid	EGFR	1.0	
Adenocarcinoma, Endometrioid	ERBB2	1.0	
Infiltrating Cervical Carcinoma	EGFR	1.0	
Infiltrating Cervical Carcinoma	ERBB2	1.0	
Other specified disorders of breast	EGFR	1.0	
Other specified disorders of breast	ERBB2	1.0	
Anaplastic carcinoma	CYP19A1	1.0	
Anaplastic carcinoma	EGFR	1.0	
Intraosseous mucoepidermoid carcinoma	EGFR	1.0	
Intraosseous mucoepidermoid carcinoma	ERBB2	1.0	
Chronic Periodontitis	FCGR2A	1.0	
Chronic Periodontitis	FCGR2B	1.0	
Chronic Periodontitis	FCGR3A	1.0	
Tumor Initiation	CYP19A1	1.0	
Tumor Initiation	EGFR	1.0	
Tumor Initiation	ERBB2	1.0	
Refractory cancer	EGFR	1.0	
Refractory cancer	ERBB2	1.0	
Early-Stage Breast Carcinoma	EGFR	1.0	
Early-Stage Breast Carcinoma	ERBB2	1.0	
Hepatosplenic schistosomiasis	EGFR	1.0	
Hepatosplenic schistosomiasis	ERBB2	1.0	
Carcinoma, Large Cell	EGFR	1.0	
Carcinoma, Large Cell	ERBB2	1.0	
{Spondyloarthropathy, susceptibility to, 1}, 106300 (3)	FCGR2A	1.0	
{Spondyloarthropathy, susceptibility to, 1}, 106300 (3)	FCGR2B	1.0	
Urothelial Carcinoma	EGFR	1.0	
Urothelial Carcinoma	ERBB2	1.0	
Urothelial Carcinoma	FCGR2A	1.0	
Urothelial Carcinoma	FCGR2B	1.0	
B-cell lymphoma	EGFR	1.0	
B-cell lymphoma	ERBB2	1.0	
B-cell lymphoma	FCGR2A	1.0	
B-cell lymphoma	FCGR2B	1.0	
B-cell lymphoma	FCGR3A	1.0	
Mucocutaneous Lymph Node Syndrome	FCGR2A	1.0	
Mucocutaneous Lymph Node Syndrome	FCGR2B	1.0	
Mucocutaneous Lymph Node Syndrome	FCGR3A	1.0	
Severe Dengue	FCGR2A	1.0	
Severe Dengue	FCGR2B	1.0	
Respiratory tract infection	EGFR	1.0	
Respiratory tract infection	FCGR2A	1.0	
Respiratory tract infection	FCGR2B	1.0	
Respiratory tract infection	FCGR3A	1.0	
Breast Cancer Model	EGFR	1.0	
Breast Cancer Model	ERBB2	1.0	
Granulomatosis with Polyangiitis	FCGR2A	1.0	
Granulomatosis with Polyangiitis	FCGR3A	1.0	
Pleural Effusion, Malignant	EGFR	1.0	
Pleural Effusion, Malignant	ERBB2	1.0	
Lymphoma, Large B-Cell, Diffuse	EGFR	1.0	
Lymphoma, Large B-Cell, Diffuse	ERBB2	1.0	
Lymphoma, Large B-Cell, Diffuse	FCGR2A	1.0	
Lymphoma, Large B-Cell, Diffuse	FCGR2B	1.0	
Lymphoma, Large B-Cell, Diffuse	FCGR3A	1.0	
Lymphoma, Large B-Cell, Diffuse	TRAF6	1.0	
Lymphoma, Large B-Cell, Diffuse	UBC	1.0	
Uterine neoplasm	CYP19A1	1.0	
Uterine neoplasm	EGFR	1.0	
Salivary gland neoplasm	EGFR	1.0	
Salivary gland neoplasm	ERBB2	1.0	
Tuberculosis, Pulmonary	EGFR	1.0	
Tuberculosis, Pulmonary	FCGR2A	1.0	
Tuberculosis, Pulmonary	FCGR3A	1.0	
Benign melanocytic nevus	EGFR	1.0	
Benign melanocytic nevus	ERBB2	1.0	
Rash and Dermatitis Adverse Event Associated with Chemoradiation	EGFR	1.0	
Rash and Dermatitis Adverse Event Associated with Chemoradiation	ERBB2	1.0	
Hormone refractory prostate cancer	EGFR	1.0	
Hormone refractory prostate cancer	ERBB2	1.0	
Hydatidiform mole, recurrent, 2	EGFR	1.0	
Hydatidiform mole, recurrent, 2	ERBB2	1.0	
Anaplastic thyroid carcinoma	CYP19A1	1.0	
Anaplastic thyroid carcinoma	EGFR	1.0	
Anaplastic thyroid carcinoma	ERBB2	1.0	
Metastatic Prostate Carcinoma	CYP19A1	1.0	
Metastatic Prostate Carcinoma	EGFR	1.0	
Metastatic Prostate Carcinoma	ERBB2	1.0	
{Diphtheria, susceptibility to} (1)	EGFR	1.0	
{Diphtheria, susceptibility to} (1)	TRAF6	1.0	
granulosa cell tumor	EGFR	1.0	
granulosa cell tumor	ERBB2	1.0	
Undifferentiated carcinoma	CYP19A1	1.0	
Undifferentiated carcinoma	EGFR	1.0	
High-Grade Squamous Intraepithelial Lesions	EGFR	1.0	
High-Grade Squamous Intraepithelial Lesions	ERBB2	1.0	
Celiac Disease	EGFR	1.0	
Celiac Disease	ERBB2	1.0	
Celiac Disease	FCGR2A	1.0	
Celiac Disease	FCGR3A	1.0	
Nasopharyngeal Neoplasms	EGFR	1.0	
Nasopharyngeal Neoplasms	ERBB2	1.0	
Alveolar rhabdomyosarcoma	EGFR	1.0	
Alveolar rhabdomyosarcoma	ERBB2	1.0	
Candidiasis, familial, 9	FCGR2A	1.0	
Candidiasis, familial, 9	FCGR3A	1.0	
Mucinous Adenocarcinoma	EGFR	1.0	
Mucinous Adenocarcinoma	ERBB2	1.0	
Soft Tissue Neoplasms	EGFR	1.0	
Soft Tissue Neoplasms	ERBB2	1.0	
Embryonal rhabdomyosarcoma	EGFR	1.0	
Embryonal rhabdomyosarcoma	ERBB2	1.0	
Carcinoid tumor no ICD-O subtype	EGFR	1.0	
Carcinoid tumor no ICD-O subtype	ERBB2	1.0	
Carcinoma, Papillary	CYP19A1	1.0	
Carcinoma, Papillary	EGFR	1.0	
Carcinoma, Papillary	ERBB2	1.0	
Disease Progression	CYP19A1	1.0	
Disease Progression	EGFR	1.0	
Disease Progression	ERBB2	1.0	
Pilocytic Astrocytoma	EGFR	1.0	
Pilocytic Astrocytoma	ERBB2	1.0	
Recurrent upper respiratory tract infections	EGFR	1.0	
Recurrent upper respiratory tract infections	FCGR3A	1.0	
Ovarian Diseases	CYP19A1	1.0	
Ovarian Diseases	FCGR2A	1.0	
Ovarian Diseases	FCGR2B	1.0	
Vestibular Schwannoma	EGFR	1.0	
Vestibular Schwannoma	ERBB2	1.0	
Adrenocortical adenoma	CYP19A1	1.0	
Adrenocortical adenoma	EGFR	1.0	
Parasitemia	FCGR2A	1.0	
Parasitemia	FCGR2B	1.0	
Periodontitis, Juvenile	FCGR2A	1.0	
Periodontitis, Juvenile	FCGR3A	1.0	
Oral Cavity Carcinoma	EGFR	1.0	
Oral Cavity Carcinoma	ERBB2	1.0	
High-Grade Prostatic Intraepithelial Neoplasia	EGFR	1.0	
High-Grade Prostatic Intraepithelial Neoplasia	ERBB2	1.0	
Bone neoplasms	EGFR	1.0	
Bone neoplasms	ERBB2	1.0	
Lupus Erythematosus, Systemic	CYP19A1	1.0	
Lupus Erythematosus, Systemic	EGFR	1.0	
Lupus Erythematosus, Systemic	ERBB2	1.0	
Lupus Erythematosus, Systemic	FCGR2A	1.0	
Lupus Erythematosus, Systemic	FCGR2B	1.0	
Lupus Erythematosus, Systemic	FCGR3A	1.0	
Lupus Erythematosus, Systemic	TRAF6	1.0	
Aortic regurgitation	CYP19A1	1.0	
Aortic regurgitation	ERBB2	1.0	
Adenocarcinoma, Clear Cell	EGFR	1.0	
Adenocarcinoma, Clear Cell	ERBB2	1.0	
Inflammatory Breast Carcinoma	EGFR	1.0	
Inflammatory Breast Carcinoma	ERBB2	1.0	
Prolactinoma, familial	EGFR	1.0	
Prolactinoma, familial	ERBB2	1.0	
Verotoxigenic Escherichia coli gastrointestinal tract infection	CYP19A1	1.0	
Verotoxigenic Escherichia coli gastrointestinal tract infection	EGFR	1.0	
Verotoxigenic Escherichia coli gastrointestinal tract infection	ERBB2	1.0	
Verotoxigenic Escherichia coli gastrointestinal tract infection	FCGR2A	1.0	
Verotoxigenic Escherichia coli gastrointestinal tract infection	FCGR3A	1.0	
Verotoxigenic Escherichia coli gastrointestinal tract infection	TRAF6	1.0	
Vesicular Stomatitis	ERBB2	1.0	
Vesicular Stomatitis	FCGR3A	1.0	
Biliary Tract Cancer	EGFR	1.0	
Biliary Tract Cancer	ERBB2	1.0	
Neutropenia	FCGR2A	1.0	
Neutropenia	FCGR2B	1.0	
Neutropenia	FCGR3A	1.0	
Dermatosis NOS	CYP19A1	1.0	
Dermatosis NOS	EGFR	1.0	
Dermatosis NOS	FCGR2A	1.0	
Dermatosis NOS	FCGR2B	1.0	
Thyroid Neoplasms	CYP19A1	1.0	
Thyroid Neoplasms	EGFR	1.0	
Thyroid Neoplasms	ERBB2	1.0	
Thyroid Neoplasms	TRAF6	1.0	
Advanced cancer	EGFR	1.0	
Advanced cancer	ERBB2	1.0	
Nephrotic syndrome, type 5, with or without ocular abnormalities	FCGR2A	1.0	
Nephrotic syndrome, type 5, with or without ocular abnormalities	FCGR2B	1.0	
Nephrotic syndrome, type 5, with or without ocular abnormalities	FCGR3A	1.0	
Abnormality of the nasopharynx	EGFR	1.0	
Abnormality of the nasopharynx	FCGR3A	1.0	
Endometrial adenocarcinoma	EGFR	1.0	
Endometrial adenocarcinoma	ERBB2	1.0	
Neuroectodermal neoplasm	EGFR	1.0	
Neuroectodermal neoplasm	ERBB2	1.0	
Endometrial Neoplasms	CYP19A1	1.0	
Endometrial Neoplasms	EGFR	1.0	
Endometrial Neoplasms	ERBB2	1.0	
Gynecomastia	CYP19A1	1.0	
Gynecomastia	ERBB2	1.0	
High grade serous carcinoma	EGFR	1.0	
High grade serous carcinoma	ERBB2	1.0	
Rhabdoid Tumor of the Kidney	EGFR	1.0	
Rhabdoid Tumor of the Kidney	ERBB2	1.0	
precancerous lesions	EGFR	1.0	
precancerous lesions	ERBB2	1.0	
Carcinoma, Small Cell	EGFR	1.0	
Carcinoma, Small Cell	ERBB2	1.0	
Mixed Salivary Gland Tumor	EGFR	1.0	
Mixed Salivary Gland Tumor	ERBB2	1.0	
Intrahepatic Cholangiocarcinoma	EGFR	1.0	
Intrahepatic Cholangiocarcinoma	ERBB2	1.0	
Neoplasm Recurrence, Local	EGFR	1.0	
Neoplasm Recurrence, Local	ERBB2	1.0	
Neoplasm Recurrence, Local	FCGR2A	1.0	
Choriocarcinoma	CYP19A1	1.0	
Choriocarcinoma	EGFR	1.0	
Choriocarcinoma	ERBB2	1.0	
Inflammatory disorder	FCGR2B	1.0	
Inflammatory disorder	FCGR3A	1.0	
Inflammatory disorder	TRAF6	1.0	
Neoplasm of the endocrine system	EGFR	1.0	
Neoplasm of the endocrine system	ERBB2	1.0	
polyps	CYP19A1	1.0	
polyps	EGFR	1.0	
polyps	ERBB2	1.0	
Herpes Simplex Infections	EGFR	1.0	
Herpes Simplex Infections	ERBB2	1.0	
Herpes Simplex Infections	FCGR2B	1.0	
Herpes Simplex Infections	FCGR3A	1.0	
Rectal Carcinoma	CYP19A1	1.0	
Rectal Carcinoma	EGFR	1.0	
Rectal Carcinoma	ERBB2	1.0	
Breast adenocarcinoma	EGFR	1.0	
Breast adenocarcinoma	ERBB2	1.0	
Mammary Ductal Carcinoma	EGFR	1.0	
Mammary Ductal Carcinoma	ERBB2	1.0	
Severe combined immunodeficiency due to ADA deficiency	EGFR	1.0	
Severe combined immunodeficiency due to ADA deficiency	ERBB2	1.0	
Severe combined immunodeficiency due to ADA deficiency	FCGR3A	1.0	
Severe combined immunodeficiency due to ADA deficiency	TRAF6	1.0	
Hereditary nonpolyposis colorectal cancer type 8	EGFR	1.0	
Hereditary nonpolyposis colorectal cancer type 8	ERBB2	1.0	
Multiple Myeloma	EGFR	1.0	
Multiple Myeloma	ERBB2	1.0	
Multiple Myeloma	FCGR2A	1.0	
Multiple Myeloma	FCGR2B	1.0	
Multiple Myeloma	FCGR3A	1.0	
Multiple Myeloma	TRAF6	1.0	
Adenocarcinoma Of Esophagus	CYP19A1	1.0	
Adenocarcinoma Of Esophagus	EGFR	1.0	
Adenocarcinoma Of Esophagus	ERBB2	1.0	
Ependymoma	EGFR	1.0	
Ependymoma	ERBB2	1.0	
Hepatitis, Autoimmune	FCGR2A	1.0	
Hepatitis, Autoimmune	FCGR2B	1.0	
Drug Eruptions	EGFR	1.0	
Decreased fertility in females	CYP19A1	1.0	
Disorder of skeletal system	EGFR	1.0	
Lobular carcinoma in situ of breast	ERBB2	1.0	
Thrombophilia	CYP19A1	1.0	
Thrombophilia	EGFR	1.0	
